Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Net Margin (2019 - 2023)

Historic Net Margin for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to 0.33%.

  • ADC Therapeutics' Net Margin fell 666400.0% to 0.33% in Q3 2023 from the same period last year, while for Dec 2023 it was 0.29%, marking a year-over-year decrease of 4800.0%. This contributed to the annual value of 74.22% for FY2022, which is 6594719100.0% up from last year.
  • Latest data reveals that ADC Therapeutics reported Net Margin of 0.33% as of Q3 2023, which was down 666400.0% from 0.24% recorded in Q2 2023.
  • ADC Therapeutics' Net Margin's 5-year high stood at 544223016.66% during Q3 2021, with a 5-year trough of 15894.14% in Q4 2019.
  • Moreover, its 5-year median value for Net Margin was 17.92% (2022), whereas its average is 39875345.36%.
  • As far as peak fluctuations go, ADC Therapeutics' Net Margin soared by 2000000000bps in 2021, and later tumbled by 2000000000bps in 2022.
  • Over the past 5 years, ADC Therapeutics' Net Margin (Quarter) stood at 15894.14% in 2019, then surged by 88304bps to 14019310.34% in 2020, then skyrocketed by 3782bps to 544223016.66% in 2021, then crashed by -100bps to 0.0% in 2022, then crashed by -952988bps to 0.33% in 2023.
  • Its Net Margin stands at 0.33% for Q3 2023, versus 0.24% for Q2 2023 and 0.31% for Q1 2023.